New Low Observer's  Instablog

New Low Observer
Send Message
As a contributor to the New Low Observer (http://www.newlowobserver.com/about-this-site), we intend to give new insights on a low risk approach to trading in dividend paying stocks for tax deferred accounts. The New Low Observer (http://www.newlowobserver.com/about-this-site) is not intended for... More
My blog:
New Low Observer
  • Abbott Labs In Review 0 comments
    Jan 2, 2013 12:13 PM | about stocks: ABT

    On September 19, 2012 (found here), we recommended that investors consider selling Abbott Labs (NYSE:ABT), at least the principal portion. At the time, ABT was trading at a split-adjusted $33. by October 16, 2012, shortly after our sell recommendation, Abbott rose as high as $34.67 or +5.06%.

    After peaking on October 16th, ABT went into a decline all the way to $29.96 or -13.59%, by November 16, 2012. The decline of ABT took the stock price to the widely followed 200-day moving average.

    (click to enlarge)

    Ordinarily, a decline to the 200-day moving average is a make or break proposition for many investors. It seems that in the case of Abbott Labs, it was a move that "made" the stock as it bounced on the 200-day moving average on two occasions at $29.96 and $30.63. The spike in the price today, after the split of AbbVie (NYSE:ABBV), has given ABT renewed life as the stock exceeded the 50-day moving average by a wide margin, the first time since falling below the 50-day in mid-October 2012.

    Unlike in the period since our accumulation of ABT shares, the stock price has languished for over 3 months. Dow Theory suggests that this is where a "line" is created, when institutions are either accumulating or distributing the stock. A "line" can last from months to years. We're taking the view that rising above $35 is an indication that institutional accumulation has won out and that much higher prices lie ahead. However, if the stock declines below the $29.96 level, we can only conclude that distribution is in effect and the price of Abbott has much lower to go.

    In the meantime, those interested in a short-term transaction can expect ABT to retest the previous high. Our expectation is that ABT will achieve the $35 level, at minimum, which is +8% above the current price ($32.33). Even if the gain is only +5%, a healthy portion of the portfolio (20%-30%) could have a meaningful impact on overall returns. The downside risk is that you'll have a company that you wouldn't mind holding on a long-term basis with an ex-dividend date approaching in the next week or two.*

    *The strategy recommended is best suited for tax-free and tax-deferred accounts.

    Stocks: ABT
Back To New Low Observer's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.